Decitabine
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Decitabine: Toward a New Predicted Indication in Refractory Cytopenia of Childhood
One-Sentence Summary
Decitabine (DrugBank DB01262) currently has no license records or original indication data available in this evidence pack, and it is not marketed in Norway. The TxGNN model predicts it may be effective for Refractory Cytopenia of Childhood, with 0 registered clinical trials and 1 supporting publication currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no license records or original indication data in evidence pack |
| Predicted New Indication | Refractory Cytopenia of Childhood |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 (single retrospective/observational study, no RCT or clinical trial registered) |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for decitabine is not available in this evidence pack. Without confirmed original indication and MOA information, a mechanistic rationale linking decitabine to Refractory Cytopenia of Childhood cannot be substantiated from the supplied evidence.
The single supporting publication describes decitabine used in combination with a minimally myelosuppressive regimen as a bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in pediatric myelodysplastic syndrome (MDS), of which refractory cytopenia of childhood is a recognized subtype. This suggests a plausible clinical context for the prediction, but the mechanistic and indication-relationship analysis cannot be completed until MOA data (DG002) is resolved.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35624441 | 2022 | Pending classification | BMC Pediatrics | Single-center 10-year experience using decitabine combined with a minimally myelosuppressive regimen as bridging therapy to allo-HSCT in pediatric MDS |
Norway Market Information
Decitabine has no license records in Norway (0 authorizations, market status: Not Marketed).
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/label warnings and contraindications (DG001) are currently a Blocking data gap — this prevents a full S1 safety pre-assessment.
Conclusion and Next Steps
Decision: Hold
Rationale:
- A blocking data gap (DG001 – TFDA label warnings/contraindications) prevents completion of the S1 safety pre-assessment, and evidence for the predicted indication is currently limited to a single retrospective/observational publication with no registered clinical trials.
To proceed, the following is needed:
- TFDA label PDF with warnings/contraindications (DG001, Blocking)
- Mechanism of action (MOA) data via DrugBank API (DG002, High)
- Additional clinical trial or higher-tier literature evidence to support the predicted indication beyond a single single-center retrospective study
- Confirmation of decitabine's original approved indication(s) to establish a mechanistic rationale
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.